TheStreet downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a c- rating to a d+ rating in a research report sent to investors on Friday.

Several other research analysts also recently weighed in on the stock. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $34.17 price target for the company in a research report on Monday, July 24th. Deutsche Bank AG cut their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating for the company in a report on Friday, May 12th. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and cut their price objective for the company from $25.00 to $13.00 in a report on Wednesday, August 23rd. Royal Bank Of Canada reiterated an outperform rating and issued a $37.00 price objective (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, July 17th. Finally, Wells Fargo & Company reiterated a market perform rating on shares of Teva Pharmaceutical Industries Limited in a report on Saturday, April 29th. Four research analysts have rated the stock with a sell rating, nineteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has a consensus rating of Hold and an average price target of $35.06.

Teva Pharmaceutical Industries Limited (TEVA) opened at 15.93 on Friday. The stock’s market capitalization is $16.18 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $15.72 and a 52-week high of $52.66. The company’s 50-day moving average price is $25.37 and its 200 day moving average price is $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the company earned $1.25 EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Downgraded to “D+” at TheStreet” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/29/teva-pharmaceutical-industries-limited-teva-downgraded-to-d-at-thestreet.html.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.13%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Institutional investors have recently modified their holdings of the stock. WFG Advisors LP boosted its position in shares of Teva Pharmaceutical Industries Limited by 2,650.1% in the second quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock valued at $989,000 after buying an additional 28,701 shares in the last quarter. Oak Associates Ltd. OH boosted its position in shares of Teva Pharmaceutical Industries Limited by 0.6% in the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock valued at $12,621,000 after buying an additional 2,114 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at approximately $373,000. Sterneck Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 5.4% in the second quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock valued at $4,382,000 after buying an additional 6,702 shares in the last quarter. Finally, Northern Cross LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares in the last quarter. 56.87% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.